Instrument Inactif

Autres langues Stayble Therapeutics AB

Actions

STABL

SE0013513652

Recherche biotechnologique et médicale

Autres langues

21/05	Stayble Therapeutics Q1 EBIT loss narrows to SEK 6.9 mln
21/05	Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Stayble Therapeutics enters into loi on potential strategic collaboration, financing
25/02	Stayble Therapeutics Q4 oper loss to SEK 1.5 mln
25/02	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
19/11	Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
27/10/25	Stayble Therapeutics updates on progress in finding partner for STA363
20/08/25	Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
20/08/25	Stayble Therapeutics Q2 EBIT loss narrows to SEK 1.9 mln
21/05/25	Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2025
21/05/25	Stayble Therapeutics Q1 EBIT Loss At About SEK 2 Mln
05/05/25	Stayble Therapeutics Carries Out Directed Issue Of Units
25/02/25	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
14/01/25	Interview with US payer expert on the US market and STA363's potential
02/01/25	Interview with Jane Buus Laursen - an experienced pharma dealmaker and Board member of Stayble
11/12/24	Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation
11/12/24	Stayble Therapeutics Reports Additional Data Strengthening the STA363 Treatment for Pain Caused by Disc Herniation
29/11/24	Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
13/11/24	Stayble Therapeutics' STA363 receives positive phase 1b results
13/11/24	Stayble Therapeutics' STA363 Receives Positive Phase 1b Results
20/08/24	Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
23/07/24	Sweden's Stayble Therapeutics Names New CFO to Start in August
23/07/24	Stayble Therapeutics Announces Chief Financial Officer Changes
21/05/24	Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024
20/02/24	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023